The fund will drive innovation, expand reach and enhance patient care
Beta Drugs, a vertically integrated oncology-focussed formulations company has raised primary capital worth Rs 117 crore from HealthQuad Fund II, (HealthQuad), and other investors including a Singapore-based investment fund and a private wealth management firm for a minority stake in the company.
Rahul Batra, CMD, Beta Drugs said “We are thrilled to welcome
HealthQuad as a partner in Beta Drugs. Their investment and expertise will play a pivotal role in accelerating our growth journey, as we strive to position ourselves among the top five oncology companies in India over the next five years. By leveraging HealthQuad’s global network and deep
knowledge of the pharmaceutical industry, we are confident in our ability to drive innovation, expand our reach, and enhance patient care.”
Ajay Mahipal, Partner at HealthQuad Capital, said, “We are excited to partner with Beta Drugs in this pivotal phase of their growth journey. HealthQuad has a strong focus on improving healthcare outcomes,
especially for underserved communities and has a positive outlook towards the future of curative oncology in India, which is echoed in Beta Drugs’ mission. Beta Drugs, with its strong manufacturing and
R&D capabilities are poised to improve affordability in the middle- and lower-income segment, and accessibility in tier II and tier III cities in the country. We believe in the transformative potential of their new product launches, expanding export markets, and experienced management team, all of which position the company for substantial growth and value creation.”